Drugs / BMN 255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06138327 | Sep 2023 → Mar 2024 | NAFLD1, nephrolithiasis, primary hyperoxaluria | BioMarin Pharmaceutical | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06138327 ↗ |
| Route | Oral | “Oral administration of BMN 255” NCT06138327 ↗ |